Rochester, MN (KROC-AM News) - The Mayo Clinic is gearing up for a Phase 2 clinical trial of a potential treatment for COVID-19.

BioSig Technologies says the investigation into the effectiveness of its product Vicromax as a therapy for the coronavirus illness is being led by Dr. Andrew D. Badley, who is the Professor and Chair of the Mayo Clinic Department of Molecular Medicine and the Enterprise Chair of Mayo's COVID-19 Task Force. A news release says the randomized, placebo-controlled trial is scheduled to begin next week.

“This trial is a part of our commitment to accelerate discoveries related to the SARS-CoV-2 virus and the disease it causes, COVID-19," says Andrew D. Badley, M.D., infectious disease expert, chair of the COVID-19 Research Task Force at Mayo Clinic.

 

“Evaluating efficacy of Vicromax ™ (MMPD) in patients is a top priority, and we are pleased that Mayo Clinic agreed to work with us on this critically important mission,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.

Data from the Phase 2 trial is expected within 3 months. BioSig and its subsidiary ViralClear Pharmaceuticals describe Vicromax as an orally administered, broad-spectrum antiviral agent that has demonstrated strong activity against the coronavirus in cell cultures through laboratory testing. The news release says the safety of the product in humans has been tested in a dozen completed Phase 1 and Phase 2 studies involving other illnesses.

News Update:  No Parole For Killer of Area Police Chief

Enter your number to get our free mobile app